Refined pharmacovigilance assessment of immune checkpoint inhibitors-related bullous pemphigoid: a multi-methodological approach utilizing FAERS database
Journal of Pharmacy & Pharmaceutical Sciences · 2026
DOI: 10.3389/jpps.2025.15597 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmacy & Pharmaceutical Sciences, 2026. Verfasst von Yan Wang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, PUMC Hospital, CAMS and PUMC, National Clinical Research Center …. Hauptthemen laut MEDLINE: Pemphigoid, Bullous, Pharmacovigilance, Immune Checkpoint Inhibitors. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
To evaluate the potential risk of bullous pemphigoid (BP) in patients treated with immune checkpoint inhibitors (ICIs) and to characterize ICI-related BP (irBP) using the United States Food and Drug Administration Adverse Event Reporting System (FAERS) database.
Methods
The present study conducted a disproportionality analysis leveraging FAERS database, spanning the first quarter (Q1) of 2004–2025 Q1. To ensure robust signal detection, we employed a quadruple analytical approach incorporating: (1) reporting odds ratio (ROR), (2) proportional reporting ratio, (3) Bayesian confidence propagation neural network, and (4) multi-item gamma Poisson shrinker algorithms. These methodologies were systematically applied to assess the potential risk of BP in patients treated with ICIs. Furthermore, temporal characteristics of adverse event emergence were quantitatively assessed to delineate the time-to-onset patterns.
Results
There are 850 irBP cases identified, comprising reports associated with the following agents: nivolumab (n = 530), pembrolizumab (n = 180), ipilimumab (n = 44), atezolizumab (n = 40), cemiplimab (n = 24), durvalumab (n = 19), tislelizumab (n = 10), and avelumab (n = 3). Affected patients were predominantly males (67.8%) and over 60 years of age (70.1%). All eight ICIs showed positive disproportionality signals, with ROR values ranked descendingly as: cemiplimab > nivolumab > tislelizumab > pembrolizumab > ipilimumab > durvalumab > atezolizumab > avelumab. The median time of irBP onset was 165.2 (IQR: 56–410) days.
Conclusion
The study establishes a significant link between ICIs and BP. All ICIs increase BP risk. CTLA-4 inhibitors exhibited the most marked early risk concentration, highlighting the importance of early dermatologic evaluation after initiating CTLA-4 blockade.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, PUMC Hospital, CAMS and PUMC, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, China.
Zitieren
APA
Wang, Y., Yang, L. Y., & Zuo, Y. G. (2026). Refined pharmacovigilance assessment of immune checkpoint inhibitors-related bullous pemphigoid: a multi-methodological approach utilizing FAERS database. Journal of Pharmacy & Pharmaceutical Sciences. https://doi.org/10.3389/jpps.2025.15597
Vancouver
Wang Y, Yang LY, Zuo YG. Refined pharmacovigilance assessment of immune checkpoint inhibitors-related bullous pemphigoid: a multi-methodological approach utilizing FAERS database. Journal of Pharmacy & Pharmaceutical Sciences. 2026. doi:10.3389/jpps.2025.15597
BibTeX
@article{Wang2026,
author = {Wang, Yan and Yang, Liu-Yi-Yi and Zuo, Ya-Gang},
title = {Refined pharmacovigilance assessment of immune checkpoint inhibitors-related bullous pemphigoid: a multi-methodological approach utilizing FAERS database},
journal = {Journal of Pharmacy & Pharmaceutical Sciences},
year = {2026},
doi = {10.3389/jpps.2025.15597}
}
EUVIMED